Here is the full press release
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose
For the non-Relvyrio participants in the trial they reported :
a 22% improvement in slope of change in ALSFRS-R assessment adjusted for mortality, with an 89% success probability, at 24 weeks
the rate of decline in ALSFRS-R slope (points per month) also favoured the SLS-005 treatment group versus placebo over 6 months (-0.80 and -1.07 points per month, respectively)
A couple of things stand out to me in these results for this subgroup :
- adjusted for mortality .... say no more !
- the rate of -.8 decline for those on SLS-005 vs -1.07 for those on placebo.
MPL ( 12 patients only )
- no mortality
- rate of decline on 10mg ( cohort 2 - 6 patients ), -.6 decline, 58% slower decline
To put it bluntly ... we win !
Here is the full press releaseSeelos Therapeutics Provides...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.010(5.88%) |
Mkt cap ! $71.26M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.5¢ | 17.5¢ | $171.0K | 947.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 167677 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 242051 | 5 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.0¢ |
Change
0.010 ( 4.35 %) |
||||
| Open | High | Low | Volume | ||
| 17.5¢ | 18.5¢ | 17.5¢ | 615808 | ||
| Last updated 15.48pm 29/05/2024 ? | |||||
| PAA (ASX) Chart |